Whilst osimertinib and targeted therapy for mutations such as anaplastic lymphoma kinase (ALK) and ROS1 have demonstrated some clinical benefit in patients lacking these EGFR mutations,16, 17 they do not fully address the broader NSCLC population without these mutations. Here, ALK is linked to non-small cell lung carcinoma.